# Five Diabetes Case Management Scenarios

## Case 1: Newly Diagnosed Type 2 Diabetes

**Patient Presentation:**

- 52-year-old male, newly diagnosed with type 2 diabetes
    
- Presents with fatigue, polyuria, and polydipsia for 3 months
    
- BMI 32 kg/m², sedentary lifestyle
    
- No known cardiovascular disease
    

**Medications:**

- None currently

**Laboratory Results:**

- HbA1c: 8.2%
    
- Fasting glucose: 165 mg/dL
    
- Creatinine: 0.9 mg/dL (eGFR >90 mL/min/1.73m²)
    
- LDL: 145 mg/dL
    
- Blood pressure: 138/88 mmHg
    

**Management Considerations:**

- **Initiate metformin** unless contraindicated, as it is the first-line pharmacologic choice for most patients\[1\]\[2\]
    
- Immediate referral to **diabetes self-management education and support (DSMES)** to address survival-level skills and establish a personal education plan\[3\]
    
- Implement **medical nutrition therapy (MNT)** with individualized meal planning considering Mediterranean or other evidence-based dietary patterns\[2\]
    
- Prescribe **physical activity**: goal of ≥150 min/week of moderate aerobic exercise plus resistance training 2-3 times per week\[2\]
    
- Assess barriers to success including psychosocial needs, health literacy, and social determinants of health\[1\]
    
- Consider statin therapy for cardiovascular risk reduction
    
- Target HbA1c <7% for most non-pregnant adults; individualize based on patient factors\[1\]
    
- Schedule follow-up in 3 months to reassess HbA1c and adjust therapy as needed
    

* * *

## Case 2: Established Diabetes with Cardiovascular Disease

**Patient Presentation:**

- 64-year-old female with 8-year history of type 2 diabetes
    
- History of myocardial infarction 2 years ago
    
- Complains of inadequate glycemic control despite current therapy
    
- BMI 28 kg/m²
    

**Medications:**

- Metformin 1000 mg twice daily
    
- Atorvastatin 40 mg daily
    
- Aspirin 81 mg daily
    
- Lisinopril 20 mg daily
    

**Laboratory Results:**

- HbA1c: 8.5%
    
- Fasting glucose: 178 mg/dL
    
- Creatinine: 1.1 mg/dL (eGFR 65 mL/min/1.73m²)
    
- LDL: 82 mg/dL
    
- Blood pressure: 132/78 mmHg
    

**Management Considerations:**

- **Add GLP-1 receptor agonist or SGLT-2 inhibitor** given established atherosclerotic cardiovascular disease (ASCVD)\[1\]
    
- GLP-1 RA preferred for additional cardiovascular benefit in patients with established ASCVD
    
- Continue metformin as tolerated
    
- Reinforce lifestyle interventions including MNT and physical activity prescription\[2\]
    
- Monitor renal function given eGFR 65 mL/min/1.73m²
    
- Assess for diabetic complications including retinopathy, neuropathy, and [nephropathy](/rare-disease/retinal-vasculopathy-with-cerebral-leukoencephalopathy-and-systemic-manifestations)
    
- Continue cardiovascular risk factor management
    

* * *

## Case 3: Uncontrolled Diabetes Requiring Intensification

**Patient Presentation:**

- 58-year-old male with 5-year history of type 2 diabetes
    
- Poor adherence to medications and lifestyle modifications
    
- Works night shifts, reports difficulty with meal planning
    
- BMI 35 kg/m²
    

**Medications:**

- Metformin 1000 mg twice daily
    
- Glipizide 10 mg twice daily
    

**Laboratory Results:**

- HbA1c: 9.8%
    
- Fasting glucose: 245 mg/dL
    
- Random glucose: 310 mg/dL
    
- Creatinine: 1.0 mg/dL (eGFR 85 mL/min/1.73m²)
    
- LDL: 128 mg/dL
    
- Blood pressure: 145/92 mmHg
    

**Management Considerations:**

- **Consider dual or triple combination therapy** given HbA1c ≥9%\[4\]
    
- Add GLP-1 RA or SGLT-2 inhibitor to existing regimen, or consider basal insulin
    
- Address **barriers to adherence**: work schedule, health literacy, social determinants of health\[1\]\[5\]
    
- Referral to DSMES for intensive education and support\[3\]
    
- Develop individualized treatment plan using person-centered, culturally sensitive communication\[5\]
    
- Consider diabetes care and education specialist involvement
    
- Assess for hypoglycemia risk with sulfonylurea use
    
- Intensify blood pressure management
    
- May require insulin therapy if oral agents insufficient
    

* * *

## Case 4: Diabetes with Heart Failure

**Patient Presentation:**

- 70-year-old female with 12-year history of type 2 diabetes
    
- Recently diagnosed with heart failure with reduced ejection fraction (HFrEF, EF 35%)
    
- Reports lower extremity edema and dyspnea on exertion
    
- BMI 31 kg/m²
    

**Medications:**

- Metformin 500 mg twice daily
    
- Sitagliptin 100 mg daily
    
- Furosemide 40 mg daily
    
- Carvedilol 12.5 mg twice daily
    

**Laboratory Results:**

- HbA1c: 7.8%
    
- Fasting glucose: 152 mg/dL
    
- Creatinine: 1.3 mg/dL (eGFR 48 mL/min/1.73m²)
    
- BNP: 850 pg/mL
    
- Blood pressure: 128/76 mmHg
    

**Management Considerations:**

- **Add SGLT-2 inhibitor** for heart failure benefit, even with eGFR 48 mL/min/1.73m²\[1\]
    
- Consider reducing or discontinuing metformin given eGFR <50 mL/min/1.73m², as guideline recommendations suggest caution below this threshold\[6\]
    
- Continue sitagliptin as DPP-4 inhibitors are safe in heart failure, though less cardiovascular benefit than SGLT-2 inhibitors
    
- Assess for diabetic complications including neuropathy and retinopathy
    
- Individualized physical activity prescription considering heart failure limitations\[2\]
    
- Regular monitoring of volume status and adjust diuretic therapy as needed
    
- Consider SGLT-2 inhibitor adjustment if eGFR declines further below 30 mL/min/1.73m²
    

* * *

## Case 5: Young Adult with Obesity and Prediabetes Progression

**Patient Presentation:**

- 38-year-old male with strong family history of type 2 diabetes
    
- Previously diagnosed with prediabetes 2 years ago
    
- Minimal lifestyle changes implemented
    
- Works sedentary office job
    
- BMI 38 kg/m²
    

**Medications:**

- None

**Laboratory Results:**

- Fasting glucose: 118 mg/dL
    
- HbA1c: 6.1%
    
- Creatinine: 0.8 mg/dL (eGFR >90 mL/min/1.73m²)
    
- LDL: 138 mg/dL
    
- Blood pressure: 132/84 mmHg
    

**Management Considerations:**

**Intensive lifestyle modification is the cornerstone of therapy** for this patient with prediabetes and obesity (BMI 38 kg/m²). Given his strong family history and minimal prior lifestyle changes, he faces approximately 10% annual risk of progression to type 2 diabetes.\[1\] His prediabetes also confers increased cardiovascular risk, with excess absolute risk of 8.75 per 10,000 person-years for cardiovascular events.\[1\]

The primary goal is **achieving 7-10% weight loss** (approximately 20-28 lbs for this patient), which has been demonstrated to be highly effective in preventing progression to type 2 diabetes.\[2\]\[3\]\[4\] This threshold represents a critical target, as weight loss of this magnitude significantly reduces diabetes incidence.\[2\]\[5\]

**Lifestyle interventions should include:**

- **Calorie restriction** with an energy deficit of 500-1000 calories/day through individualized meal planning\[5\]
    
- **Mediterranean or DASH diet** emphasizing non-starchy vegetables, whole grains, and pulses\[2\]\[8\]
    
- **Physical activity prescription**: ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking) over 3-5 sessions, plus resistance training 2-3 times per week targeting major muscle groups\[2\]\[3\]\[9\]
    
- **Behavioral support** including self-monitoring of food intake and exercise, motivational support, and strategies to reduce sedentary behavior during his office job\[1\]\[2\]\[4\]
    
- **Referral to diabetes self-management education and support (DSMES)** and medical nutrition therapy (MNT) delivered by registered dietitian nutritionist\[4\]\[5\]
    

**Metformin should be strongly considered** for this patient, as he meets multiple high-risk criteria: age <60 years, BMI ≥35 kg/m², HbA1c ≥6.0%, and strong family history of diabetes\[1\]\[3\] The American Diabetes Association specifically recommends metformin for individuals matching this profile\[3\] In the Diabetes Prevention Program, metformin reduced diabetes incidence by 3.2 cases per 100 person-years over 3 years, though lifestyle modification showed greater benefit (6.2 cases per 100 person-years reduction)\[1\]

**Weight-loss pharmacotherapy should be considered** if lifestyle measures alone are insufficient to achieve the 7-10% weight loss goal\[3\]\[4\]\[2\] FDA-approved options with efficacy for weight loss and diabetes prevention include:

- GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg)
    
- Tirzepatide (approved for obesity management)
    
- Phentermine/topiramate extended-release\[3\]\[2\]
    

These medications have demonstrated effectiveness in decreasing type 2 diabetes incidence in individuals with prediabetes.\[3\]

**Bariatric procedures should be considered** if BMI remains >35 kg/m² despite lifestyle interventions and pharmacotherapy, as they are more effective than lifestyle interventions and medications for weight reduction.\[2\]

**Monitoring and follow-up:**

- Regular assessment of weight, glycemic status (HbA1c or fasting glucose), and cardiovascular risk factors
    
- Intensive follow-up to support adherence and behavior modification
    
- If metformin is initiated, periodic vitamin B12 assessment, especially if anemia or peripheral neuropathy develops\[3\]
    
- Address psychosocial barriers, health literacy, and social determinants of health that may impact adherence\[2\]\[4\]
    

**Additional considerations:**

- Initiate statin therapy for cardiovascular risk reduction given LDL 138 mg/dL
    
- Address blood pressure (132/84 mmHg) with lifestyle modification; consider pharmacotherapy if persistently elevated
    
- Screen for other obesity-related comorbidities including obstructive sleep apnea, nonalcoholic fatty liver disease, and osteoarthritis
    

Would you like me to review the evidence and guidelines regarding the initiation of metformin in patients with prediabetes and high-risk features, specifically focusing on its long-term efficacy, safety, and impact on diabetes prevention?

* * *

## Case 6: Latent Autoimmune Diabetes in Adults (LADA)

**Patient Presentation:**

- 42-year-old female presenting with gradual onset of hyperglycemia over 6 months
    
- Initially thought to have type 2 diabetes but **failed to respond adequately to oral agents**
    
- Reports unintentional weight loss of 8 pounds despite medication
    
- BMI 24 kg/m² (normal weight)
    
- No family history of type 2 diabetes, but maternal aunt has type 1 diabetes and hypothyroidism
    
- Works as a teacher, moderately active lifestyle
    

**Medications:**

- Metformin 1000 mg twice daily (started 4 months ago)
    
- Glipizide 10 mg daily (added 2 months ago due to inadequate control)
    

**Laboratory Results:**

- HbA1c: 8.9% (despite oral therapy)
    
- Fasting glucose: 198 mg/dL
    
- **Random C-peptide: 0.52 nmol/L** (low-normal, suggesting reduced insulin secretion)
    
- **GAD antibodies: positive** (elevated at 45 U/mL; normal 90 mL/min/1.73m²)
    
- TSH: 2.1 mIU/L (normal)
    
- LDL: 118 mg/dL
    
- Blood pressure: 124/78 mmHg
    

**Management Considerations:**

- **Discontinue sulfonylurea immediately**, as sulfonylureas may accelerate β-cell failure in LADA and lead to earlier insulin dependence\[1\]\[2\]
    
- **Initiate insulin therapy** given C-peptide in the "gray area" (0.3-0.7 nmol/L), where the international expert panel recommends a modified treatment approach with insulin in combination with other therapies\[1\]
    
- **Continue metformin** if tolerated, as it may provide additional metabolic benefit without accelerating autoimmune β-cell destruction\[1\]\[3\]
    
- Consider adding a **GLP-1 receptor agonist** for potential β-cell protective effects and additional glycemic control, though evidence in LADA is limited\[3\]\[4\]
    
- **Monitor C-peptide levels** every 6-12 months to assess progression of β-cell failure and adjust insulin dosing accordingly\[1\]\[5\]
    
- Provide education about the **progressive nature of LADA** and the likelihood of increasing insulin requirements over time\[6\]\[7\]
    
- Screen for other **autoimmune conditions** (thyroid disease, celiac disease, Addison's disease) given the autoimmune nature of LADA\[7\]
    
- Emphasize that this is **not type 2 diabetes** and requires a different therapeutic approach focused on preserving remaining β-cell function\[6\]
    
- Avoid labeling as "type 2 diabetes" in medical records to prevent future therapeutic errors
    
- Consider referral to endocrinology for specialized management of autoimmune diabetes
    
- Individualize treatment plan based on rate of C-peptide decline and patient preferences
    

* * *

## Case 7: Insulin Initiation and Management in Type 2 Diabetes

**Patient Presentation:**

- 61-year-old female with 10-year history of type 2 diabetes
    
- Presents with persistent hyperglycemia despite maximally tolerated oral therapy
    
- Reports increased fatigue and nocturia over past 3 months
    
- BMI 29 kg/m², history of hypertension and hyperlipidemia
    
- No known cardiovascular disease or chronic kidney disease
    

**Medications:**

- Metformin 1000 mg twice daily
    
- Glimepiride 4 mg daily
    
- Lisinopril 10 mg daily
    
- Atorvastatin 20 mg daily
    

**Laboratory Results:**

- HbA1c: 9.2%
    
- Fasting glucose: 198 mg/dL
    
- Creatinine: 0.9 mg/dL (eGFR >90 mL/min/1.73m²)
    
- LDL: 95 mg/dL
    
- Blood pressure: 136/82 mmHg
    
- Urine albumin-to-creatinine ratio: 18 mg/g (normal)
    

**Management Plan:**

**Insulin Initiation:**

- **Discontinue glimepiride immediately** to reduce hypoglycemia risk once insulin is started\[1\]\[2\]
    
- **Initiate basal insulin glargine U-100** at 10 units subcutaneously once daily at bedtime\[2\]\[3\]
    
- Continue metformin as it provides complementary glucose-lowering and may reduce insulin requirements\[1\]\[2\]
    
- Consider adding GLP-1 RA before or concurrent with insulin for additional cardiovascular benefit and to reduce weight gain and hypoglycemia risk\[1\]
    

**Titration Protocol:**

- **Increase insulin dose by 2 units every 3 days** based on fasting glucose measurements until target of 80–130 mg/dL is achieved\[4\]\[2\]\[3\]
    
- Alternative approach: increase by 2–4 units once or twice weekly for more gradual titration\[3\]
    
- Expected final dose typically 0.3–0.5 units/kg/day, though some patients may require up to 1.0 units/kg/day\[3\]
    
- Monitor for **overbasalization** (bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, high glucose variability)\[2\]
    

**Patient Education and Monitoring:**

- Provide comprehensive education on **self-monitoring of blood glucose** (fasting and pre-dinner initially), injection technique, insulin storage, and self-titration\[1\]\[5\]
    
- Teach recognition and treatment of hypoglycemia; prescribe glucagon emergency kit\[1\]
    
- Emphasize that insulin pens are user-friendly and should never be shared between patients\[4\]
    
- Schedule follow-up in 2–4 weeks to assess titration progress and adherence
    

**Intensification Strategy (if needed after 3–6 months):**

If fasting glucose reaches target but HbA1c remains >7% or postprandial glucose >180 mg/dL:

- **Add GLP-1 RA** if not already prescribed (preferred option to minimize hypoglycemia and weight gain)\[2\]
    
- Alternatively, **add prandial insulin** starting with 4 units (or 10% of basal dose) before the largest meal, then expand to other meals as needed\[2\]
    
- Consider **premixed insulin** twice daily (e.g., 70/30) for patients with regular meal patterns who prefer simplicity\[5\]\[1\]
    

**Special Considerations:**

- **Biosimilar insulin glargine** (glargine-yfgn or glargine-aglr) may be substituted for cost savings with equivalent efficacy\[4\]
    
- If true 24-hour basal coverage is needed, consider switching to **insulin degludec or glargine U-300**, which have lower nocturnal hypoglycemia risk\[2\]\[5\]
    
- Maintain **cardiorenal protective agents** (metformin, consider adding SGLT2 inhibitor) throughout insulin therapy\[1\]\[2\]
    
- Discontinue DPP-4 inhibitors if GLP-1 RA is added (do not use together)\[2\]
    

**Expected Outcomes:**

- Target HbA1c <7% for most non-pregnant adults\[2\]\[3\]
    
- Expect gradual HbA1c reduction of approximately 1.5-2% with basal insulin addition
    
- Reassess therapy and titrate insulin doses every 2-3 days based on fasting glucose patterns
    
- Monitor for hypoglycemia (risk increases with insulin therapy) and adjust doses accordingly
    
- The emphasis on discontinuing sulfonylureas, maintaining metformin, and considering GLP-1 RA reflects current evidence-based practice prioritizing safety and cardiorenal protection\[1\]\[2\]
    

* * *

## Case 8: Addition of Bolus Insulin to Optimized Basal Insulin Therapy

**Patient Presentation:**

- 67-year-old male with 14-year history of type 2 diabetes
    
- Currently on optimized basal insulin therapy with adequate fasting glucose control
    
- Reports fatigue in afternoons, particularly after lunch
    
- BMI 30 kg/m², history of hypertension and hyperlipidemia
    
- No known cardiovascular disease or chronic kidney disease
    
- Retired accountant, sedentary lifestyle with regular meal patterns
    

**Medications:**

- Insulin glargine U-100: 48 units subcutaneously at bedtime (0.6 units/kg/day)
    
- Metformin 1000 mg twice daily
    
- Lisinopril 20 mg daily
    
- Atorvastatin 40 mg daily
    

**Laboratory Results:**

- HbA1c: 8.1% (unchanged from 3 months ago despite basal insulin titration)
    
- Fasting glucose: 115 mg/dL (consistently 100-125 mg/dL on home monitoring)
    
- Pre-lunch glucose: 185 mg/dL
    
- Pre-dinner glucose: 210 mg/dL
    
- 2-hour post-lunch glucose: 245 mg/dL
    
- Bedtime-to-morning glucose differential: 65 mg/dL (suggesting overbasalization)
    
- Creatinine: 1.0 mg/dL (eGFR 82 mL/min/1.73m²)
    
- LDL: 88 mg/dL
    
- Blood pressure: 128/76 mmHg
    

**Clinical Assessment and Rationale for Bolus Insulin:**

This patient demonstrates **clear indications for prandial insulin intensification**: fasting glucose at target but HbA1c >8%, significant postprandial hyperglycemia (>180 mg/dL), and signs of overbasalization with a bedtime-to-morning differential >50 mg/dL.\[1\]\[2\] The basal insulin dose of 0.6 units/kg/day exceeds the typical threshold of 0.5 units/kg/day where prandial coverage should be considered.\[2\]

While adding a GLP-1 receptor agonist would be a reasonable alternative to minimize hypoglycemia and weight gain, this patient's significant postprandial excursions and already high basal insulin dose make bolus insulin the more direct approach to address mealtime hyperglycemia.\[1\]\[3\]\[4\]

**Bolus Insulin Initiation:**

**Start with rapid-acting insulin analog (aspart, lispro, or glulisine) 4-5 units before dinner**, the meal with the largest postprandial excursion.\[1\]\[4\] This represents approximately 10% of his current basal dose (48 units).\[1\]\[4\]

Rapid-acting analogs are preferred over regular human insulin because they more closely mimic physiologic insulin secretion and reduce postprandial glucose excursions more effectively.\[5\] The insulin should be administered **15 minutes before the meal** for optimal effect.\[5\]

**Reduce basal insulin to 40 units** (approximately 15-20% reduction) to account for the added prandial coverage and reduce hypoglycemia risk, particularly overnight.\[1\]

Provide comprehensive education on injection technique, timing relative to meals, recognition and treatment of hypoglycemia, and proper insulin pen use. Prescribe a glucagon emergency kit.\[4\]\[6\]

**Dose Titration Protocol:**

**Titrate prandial insulin by 1-2 units (or 10-15%) twice weekly** based on pre-bedtime glucose readings, targeting 80-130 mg/dL\[4\]\[7\] For example:

- If bedtime glucose >200 mg/dL: increase dinner insulin by 2 units
    
- If bedtime glucose 180-200 mg/dL: increase by 1 unit
    
- If bedtime glucose <70 mg/dL or patient experiences hypoglycemia: decrease dinner insulin by 2 units\[7\]
    

Once dinner insulin is optimized (typically 8-12 units), **assess pre-dinner glucose**. If consistently >180 mg/dL, add 4 units of rapid-acting insulin before lunch\[1\]\[4\]\[7\] Repeat the titration process for lunch insulin based on pre-dinner readings.

If needed after optimizing lunch insulin, add breakfast prandial insulin (4 units initially) if pre-lunch glucose remains >180 mg/dL\[1\]\[4\]

**For hypoglycemia management**:\[2\]\[7\]

- If glucose <70 mg/dL, reduce the insulin dose causing hypoglycemia by 10-20%\[1\]\[6\]
    
- Educate patient on recognition and treatment of hypoglycemia given increased risk with prandial insulin
    
- Consider continuous glucose monitoring (CGM) for more comprehensive glucose pattern assessment and to reduce hypoglycemia risk\[7\]
    

**Continue metformin** throughout insulin intensification for complementary glucose-lowering and potential cardiovascular benefit\[1\]\[4\] **Do not add sulfonylureas or meglitinides**, as these increase hypoglycemia risk without additional cardiovascular or renal benefits\[1\] If a DPP-4 inhibitor were present, it should be discontinued\[1\]\[7\]

**Consider adding an SGLT-2 inhibitor or GLP-1 receptor agonist** if patient has cardiovascular disease or CKD for additional cardiorenal protection beyond glucose control\[1\]\[3\]

* * *

## Case 9: Complex Diabetes with CKD, Heart Failure, and Polypharmacy

**Patient Presentation:**

- 72-year-old male with 18-year history of type 2 diabetes
    
- **Multiple comorbidities**: heart failure with reduced ejection fraction (HFrEF, EF 28%), chronic kidney disease stage 3b, hypertension, dyslipidemia, and coronary artery disease with prior stent placement 4 years ago
    
- Reports progressive dyspnea on exertion, lower extremity edema worsening over 2 months
    
- Complains of fatigue and difficulty adhering to complex medication regimen
    
- Recent hospitalization for acute decompensated heart failure 6 weeks ago
    
- BMI 33 kg/m², sedentary due to dyspnea and fatigue
    
- Lives alone, daughter assists with grocery shopping weekly
    
- Fixed income, concerned about medication costs
    

**Medications:**

- Insulin glargine U-100: 38 units subcutaneously at bedtime
    
- Insulin aspart: 8 units before meals (inconsistently taken)
    
- Metformin 500 mg twice daily
    
- Glimepiride 4 mg daily
    
- Furosemide 80 mg twice daily
    
- Carvedilol 25 mg twice daily
    
- Sacubitril/valsartan 49/51 mg twice daily
    
- Atorvastatin 80 mg daily
    
- Aspirin 81 mg daily
    
- Spironolactone 25 mg daily
    

**Laboratory Results:**

- HbA1c: 8.7%
    
- Fasting glucose: 165 mg/dL
    
- Random glucose: 245 mg/dL
    
- Creatinine: 1.8 mg/dL (eGFR 38 mL/min/1.73m²)
    
- Potassium: 5.2 mEq/L
    
- BNP: 1,250 pg/mL (elevated from 850 pg/mL 3 months ago)
    
- Urine albumin-to-creatinine ratio: 450 mg/g (albuminuric CKD)
    
- LDL: 72 mg/dL
    
- Blood pressure: 142/86 mmHg
    
- Hemoglobin: 11.2 g/dL (anemia of CKD)
    

**Management Considerations:**

**Medication Optimization - Cardiorenal Protection Priority:**

- **Initiate SGLT-2 inhibitor immediately** (dapagliflozin 10 mg daily) given the combination of HFrEF, CKD with albuminuria, and type 2 diabetes. SGLT-2 inhibitors reduce cardiovascular death, heart failure hospitalization, and CKD progression independent of glycemic control.\[1\]\[2\]
    
- **Discontinue glimepiride** to reduce hypoglycemia risk, particularly given CKD stage 3b where sulfonylureas have prolonged duration of action and increased hypoglycemia risk.\[3\]
    
- **Reduce or discontinue metformin** given eGFR 38 mL/min/1.73m². While metformin can be continued with caution at eGFR 30-45 mL/min/1.73m², the dose should be reduced to 500 mg daily maximum or discontinued entirely given borderline eGFR and polypharmacy concerns.
    
- **Simplify insulin regimen** to reduce treatment burden and medication errors. Consider transitioning from basal-bolus to basal insulin only (glargine 40-45 units at bedtime) or premixed insulin twice daily (70/30, 20 units before breakfast and 15 units before dinner). Given his inconsistent prandial insulin use, a simpler regimen will improve adherence.\[4\]
    
- **Add GLP-1 receptor agonist** (semaglutide 0.5 mg weekly subcutaneously, titrate to 1 mg) for additional cardiovascular benefit, given established ASCVD and to potentially allow insulin dose reduction. GLP-1 RAs reduce major adverse cardiovascular events in patients with established ASCVD.\[1\]\[5\]
    

**Addressing Clinical Complexity:**

- **Hyperkalemia management**: Monitor potassium closely with SGLT-2 inhibitor initiation. Consider reducing spironolactone to 12.5 mg daily or holding temporarily if potassium remains >5.0 mEq/L, though mineralocorticoid receptor antagonists provide additional cardiorenal benefit\[2\]
    
- **Anemia of CKD**: Check iron studies, consider erythropoiesis-stimulating agent if iron replete and hemoglobin <10 g/dL\[4\]\[6\]
    
- **Volume management**: Monitor closely for worsening edema, adjust diuretics as needed given heart failure and CKD
    

**Reducing Treatment Burden:**

- **Medication consolidation**: The patient takes 10 medications daily with complex dosing schedules. Simplifying the insulin regimen and discontinuing glimepiride reduces pill burden from 10 to 8-9 medications
    
- **Cost considerations**: Discuss biosimilar insulin options and patient assistance programs for SGLT-2 inhibitor and GLP-1 RA, as cost is a barrier. If GLP-1 RA is unaffordable, prioritize SGLT-2 inhibitor given stronger heart failure and CKD benefits
    
- **Referral to diabetes care and education specialist** for comprehensive self-management education and medication management support
    
- **Coordinate care with cardiology and nephrology** given multiple organ system involvement\[7\]
    
- **Simplify medication regimen** where possible to improve adherence and reduce polypharmacy burden
    

* * *

## Case 10: Insulin Management in Type 1 Diabetes Mellitus

**Patient Presentation:**

- 28-year-old female presenting with **3-week history of polyuria, polydipsia, and unintentional weight loss** of 12 pounds
    
- Reports fatigue, blurred vision, and increased thirst despite drinking fluids
    
- No prior history of diabetes; maternal grandfather had type 1 diabetes
    
- BMI 22 kg/m² (normal weight)
    
- Works as a graphic designer, moderately active lifestyle
    
- Presents to emergency department with blood glucose 385 mg/dL, mild ketonuria, but **no diabetic ketoacidosis**
    
- Motivated to learn diabetes self-management
    

**Medications:**

- None prior to diagnosis

**Laboratory Results:**

- Random glucose: 385 mg/dL
    
- HbA1c: 10.8%
    
- Serum ketones: 1.2 mmol/L (mild ketonemia)
    
- **GAD antibodies: positive** (68 U/mL; reference <5 U/mL)
    
- eGFR: >90 mL/min/1.73m²
    
- TSH: 2.4 mIU/L (normal)
    
- Lipid panel: within normal limits
    

**Management Considerations:**

**Initial Insulin Regimen:**

**Multiple daily injections (MDI) with basal-bolus therapy** is initiated, combining long-acting basal insulin with rapid-acting prandial insulin.\[1\]\[2\] This approach mimics physiologic insulin secretion and provides the foundation for intensive diabetes management.

**Starting total daily dose (TDD):** 0.5 units/kg/day = **30 units/day** (patient weighs 60 kg).\[1\]\[3\] This is a typical starting dose for metabolically stable adults with newly diagnosed type 1 diabetes who present outside of ketoacidosis.

**Basal insulin (40-50% of TDD):**

- **Insulin glargine U-100: 14 units subcutaneously once daily at bedtime**\[1\]\[3\]
    
- Long-acting basal analogs (glargine, detemir, or degludec) provide consistent 24-hour coverage with lower hypoglycemia risk compared to NPH insulin\[1\]\[2\]
    
- Alternatively, insulin degludec or glargine U-300 may be considered for even more stable basal coverage with reduced nocturnal hypoglycemia risk
    

**Prandial insulin (50-60% of TDD):**

- **Insulin aspart (rapid-acting analog): 5 units before each meal** (breakfast, lunch, dinner), totaling 15 units/day\[1\]\[3\]
    
- Rapid-acting analogs (aspart, lispro, glulisine) are preferred over regular human insulin due to faster onset, earlier peak, and shorter duration, resulting in better postprandial glucose control and less hypoglycemia\[1\]\[2\]
    
- Administer **15 minutes before meals** for optimal postprandial coverage
    
- Ultra-rapid-acting analogs or inhaled insulin are alternatives that may provide even faster action\[1\]\[3\]
    

**Dosing Adjustment Strategies:**

**Insulin-to-carbohydrate ratio (ICR)** for prandial dosing:

- **Starting ICR: 1:15** (1 unit of insulin per 15 grams of carbohydrate)\[3\]
    
- Alternative calculation: **500 ÷ TDD = 500 ÷ 30 = 1:17 ICR** for rapid-acting insulin\[3\]
    
- Adjust ICR based on 2-hour postprandial glucose: if consistently >180 mg/dL, decrease ratio (e.g., 1:12); if consistently <120 mg/dL, increase ratio (e.g., 1:18)\[3\]
    

**Insulin sensitivity factor (ISF)** for correction dosing:

- **Starting ISF: 1800 ÷ TDD = 1800 ÷ 30 = 60 mg/dL per unit** of rapid-acting insulin\[3\]
    
- This estimates how much 1 unit of insulin will lower blood glucose
    
- Use ISF to calculate correction doses for premeal or between-meal hyperglycemia: (current glucose - target glucose) ÷ ISF
    
- For example, if glucose is 220 mg/dL and target is 100 mg/dL: (220 - 100) ÷ 60 = 2 units correction dose
    
- Adjust ISF if correction doses consistently overshoot or undershoot target
    

**Basal insulin titration:**

- Adjust basal insulin by **1-2 units every 2-3 days** based on fasting glucose, targeting 80-130 mg/dL\[1\]
    
- If fasting glucose consistently >130 mg/dL: increase basal by 2 units
    
- If fasting glucose consistently <70 mg/dL: decrease basal by 2 units\[1\]\[2\]
    
- **Menstrual cycle:** May require 10-20% increase in insulin during late luteal phase due to hormonal effects
    
- **Illness or stress:** May require temporary 10-30% increase in basal and prandial insulin
    
- Consider continuous glucose monitoring (CGM) for real-time glucose data to optimize insulin adjustments and reduce hypoglycemia risk\[1\]\[2\]